GU Cancers 2022 | Phase 2 trial of CV301 vaccine plus atezolizumab in advanced urothelial carcinoma

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase II, single-arm multicenter trial designed to evaluate CV301, comprising of two recombinant poxviruses, plus atezolizumab as a first-line treatment for patients with advanced urothelial carcinoma ineligible for cisplatin-based chemotherapy, regardless of PD-L1 status. This combination exhibited an acceptable safety profile but did not demonstrate sufficient efficacy in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.